RNS Dissection6 Jun 2020 23:02
So looking into the final RNS of the day posted by the CEO, I notice 4 major points of interest.
The first is the heavily over subscribed subscription, Instituitions must have been given a mouth watering look into the potential of the company.
with the curent climate how it is, companies are tightening up their belts and reluctant to give away money in uncertain times. So to get given more money than they anticipated speaks volume in my book.
Secondly. The company has a number of products that seem to have good potential, and are wanting to ACCELERATE these products. and accelerate is the word that they used !
To me they want to push these products forward quicker. !
Now to the CORVID test they have developed. They want £10 million !! to RAPIDILY expand this product, which tells me they are confident and want to manufacture it fast. £10 million will be enough to see them to the revenue side as this will come quickly.
Thirdly, Substantial US invester, !!!!
This is very strategic IMHO, in that by having this invester on board it may be a way into the US via the backdoor or and the invester may have the right distribution already in place.
Fourthly please find below the CEOs comment as in the RNS
The Board anticipates strong near-term news flow relating to the COVID-19 test developments with Cytiva and Adeptrix, as well as commercial and technical progress in the established therapeutic and diagnostics businesses, allowing the Company to concurrently achieve multiple value inflection points that we expect will deliver substantial shareholder returns. I look forward to updating the market on our continued progress."
So as the CEO points out, we shall have very strong news flow very very shortly, that will deliver very strong shareholder returns,
To me, that indicates that the share price is going to rise significantly in the near term, and looking into the future, potential dividends if vast amounts of profits are made, but the latter is guess work and crystal ball